HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Appendix Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Maloney, A. Articles by Simonsson, U. S. H. Search for Related Content PubMed PubMed Citation Articles by Maloney, A. Articles by Simonsson, U. S. H. Social Bookmarking                   What's this?

Optimal Adaptive Design in Clinical Drug Development: A Simulation Example

From the Department of Pharmaceutical Biosciences and the Division of Pharmacokinetics and Drug Therapy, Uppsala University, Uppsala, Sweden (Mr Maloney, Dr Karlsson, Dr Simonsson); Exprimo NV, Lummen, Belgium (Mr Maloney); and AstraZeneca, Molndal, Sweden (Dr Simonsson).

The objective of this article is to demonstrate optimal adaptive design as a methodology for improving the performance of phase II dose-response studies. Optimal adaptive design uses both information prior to the study and data accrued during the study to continuously update and refine the study design. Dose-response models include linear, log-linear, 4-parameter sigmoidal E_max, and exponential models. Where the response has both a placebo effect and plateau at higher doses, only the 4-parameter sigmoidal E_max model behaves acceptably and hence is used to illustrate the methodology. Across 13 hypothetical dose-response scenarios considered, it was shown that the capability of the adaptive designs to "learn" the true dose response resulted in performances up to 180% more efficient than the best fixed optimal designs. This work exposes the common misconception that adaptive designs are somehow "risky." As shown in this simple simulation example, the converse is true. Adaptive designs perform extremely well both when prior information is accurate and inaccurate. This leads to improved dose-response models and dose selection in phase III. This benefits sponsors, regulators, and subjects alike by reducing sample size, increasing information, and providing better dose guidance.

Key Words: Adaptive • optimal • E_max • phase II • dose response

Address for correspondence: Alan Maloney, University of Uppsala, Friggs Grand 4, Halmstad, Sweden; e-mail: al.maloney{at}exprimo.com.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. Hennig, J. Nyberg, A. C. Hooker, and M. O. Karlsson Trial Treatment Length Optimization With an Emphasis on Disease Progression Studies J. Clin. Pharmacol., March 1, 2009; 49(3): 323 - 335. [Abstract] [Full Text] [PDF]

				R. Krishna Quantitative Clinical Pharmacology: Guidance for Authors and a Call for Papers J. Clin. Pharmacol., August 1, 2008; 48(8): 898 - 899. [Full Text] [PDF]